Browsing: Commentary
Opinion and observations from life risk industry insiders, academics and policy makers
It’s not unrealistic for institutional, end investors to expect – and receive – double digit IRRs from their allocations to…
As we enter the 4th year of the COVID-19 pandemic and as the number of infected survivors grows ever larger,…
The climate crisis has both direct and indirect impacts on human health, and we stand at a dire crossroads in terms of human health
The option to sell one’s life insurance policy in the life settlement market is an attractive one. Whether individuals need…
The Covid-19 pandemic has caused a dramatic shock to health and life expectancy, disrupting the pattern of mortality improvement seen…
Interest in the life settlement asset class, the purchase of an unwanted and unneeded life insurance policy for a lump…
Actuarial Risk Management’s Cory Zass looks at what 2023 might have in store for the life settlement market
Celent’s Rob Norris offers his views on terminology in the insurtech market and what he real technology to emphasise is
In the past 40 years, life expectancy has increased significantly as a result of a range of factors, including advancements…
The concept of a life settlement investment is quite simple: the collected death benefits must exceed the cost (purchase price,…